The U.S. Food and Drug Administration anticipates a promising but challenging upswing in investigational new drug applications for cell and gene therapy products in the next five years. To take full advantage of this growing pipeline of new treatments, it will be important to adopt public policies designed to alleviate the regulatory, reimbursement, and clinical adoption challenges that make it difficult for clinicians and patients to access these therapies. In this context, the co-chairs of the Congressional Personalized Medicine Caucus organized a virtual educational briefing titled Promoting Innovation and Delivery of Cell and Gene Therapies on April 28, 2022.
You can use the links provided below to watch a video recording of the briefing or download a PDF summary of the discussions.
» View Now: "Promoting Innovation and Delivery of Cell and Gene Therapies"
Kyrsten Sinema (D-AZ)
Tim Scott (R-SC)
Eric Swalwell (D-CA)
Tom Emmer (R-MN)